LONDON--(BUSINESS WIRE)--According to the latest market research study released by Technavio, the global deep brain stimulation market is expected to exceed USD 906 billion by 2020, growing at a CAGR of almost 11% during the forecast period.

This research report titled ‘Global Deep Brain Stimulation (DBS) Market 2016-2020’, provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes an up to date analysis and forecast for various market segments and all geographical regions.

Request sample report: http://goo.gl/fl5KwR

The report segments the DBS market by application and can be divided into four broad segments:

Parkinson's Disease
Dystonia
Obsessive-Compulsive Disorder
Epilepsy
Parkinson's Disease

According to the Parkinson's Disease Foundation, around 10 million people have Parkinson's Disease (PD) worldwide. DBS system is implanted in patients whose PD symptoms such as tremor, rigidity, stiffness, slow movement, and walking disability cannot be treated with medicines. For such cases, MRI scanning is done to identify the diseased area in the brain, which helps physicians to implant the electrodes that stimulate the motor neuron.

Medtronic is leading the market with its technologically advanced product lines. Vendors such as Boston Scientific developed Vercise Deep Brain Stimulation System for PD for its product expansion. “As a result of technological innovation and clinical expansion, PD occupied 76% share of the global DBS market,” says Barath Palada, lead analyst at Technavio for patient monitoring devices research.

Dystonia

Dystonia is a neurological disorder characterized by slow repetitive movements or abnormal body postures. The disease causes involuntary muscle contraction, which makes movement painful. Surgeons suggest DBS therapy when medications cannot alleviate the symptoms. Activa Dystonia Therapy Kit, Vercise Deep Brain Stimulation System, and Medtronic Deep Brain Stimulation Therapy are some of the therapies used to treat this disease.

In the US, DBS therapy for dystonia is approved under a specific condition known as Humanitarian Device Exemption as extensive clinical research is not carried out for dystonia. In European countries, Vercise Deep Brain Stimulation System, approved by Conformité Européenne (CE) in November 2013, is used for the treatment of neurological movement disorder, intractable primary and secondary dystonia, and involuntary muscle contraction. Dystonia accounted for a 10% share of the global DBS market in 2015.

Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder (OCD) is a common chronic brain disorder often leading to disturbing and uncontrollable thoughts (obsession), which in turn leads to anxiety or discomfort in the person's behavior (compulsions). Reclaim DBS therapy, which received approval by the FDA based on Humanitarian Device Exemption in February 2009, is used to treat this disorder.

According to the FDA, this device may alleviate the symptoms to a certain extent but cannot cure OCD. The Humanitarian Device Exemption was based on the clinical study data in 26 patients who underwent DBS therapy for the treatment-resistant OCD, which treated 40% of symptoms for 12 months.

Epilepsy

Epilepsy is a neurological disorder characterized by unpredictable seizures. DBS therapy is considered for epilepsy when the seizures cannot be controlled with medicines. In September 2010, Medtronic received CE approval for its Medtronic Deep Brain Stimulation Therapy for the partial onset of seizures in adults.

“In order to provide additional data to the FDA for its approval, the company conducted a five-year trial pivotal clinical study,” says Barath. The clinical study data was published in February 2015 seeking FDA approval to enter the US market. According to the CDC, in 2015, around 2.9 million people in the US had epilepsy. Epilepsy accounted for a 5% share of the global DBS market in 2015.

Technavio’s healthcare and life sciences analysts highlight the following three vendors as the top contributors to the global deep brain stimulation market:

Boston Scientific
Medtronic
St. Jude Medical
Browse Related Reports:

Global Restless Legs Syndrome Market 2015-2019
Brain Monitoring Devices - Global Market Research 2015-2019
Epilepsy Market in the US 2015-2019
Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com